Capricor Therapeutics
8840 Wilshire Blvd
2nd Floor
Beverly Hills
California
90211
United States
211 articles about Capricor Therapeutics
-
New Capricor Data Signals Hope for Difficult-to-Treat Duchenne Muscular Dystrophy Population
9/24/2021
Capricor announced positive final data from the HOPE-2 trial of its drug candidate. It showed a slowing of disease progression in Duchenne muscular dystrophy patients. -
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
9/24/2021
Capricor Therapeutics, a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced positive final data from the HOPE-2 clinical trial using CAP-1002 to treat patients in advanced stages of Duchenne muscular dystrophy.
-
Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
9/22/2021
Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marbán, Ph.D., Capricor’s CEO, will present at the following upcoming conferences.
-
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference-Conference Dates: September 13–15, 2021-
9/7/2021
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marbán, Ph.D., Capricor’s CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
-
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
9/2/2021
Capricor Therapeutics, a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced that the Company will present final data from its HOPE-2 clinical trial with asset CAP-1002 at this year’s World Muscle Society Virtual Congress.
-
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8/12/2021
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today reported its financial results for the second quarter ended June 30, 2021, and provided an overview of its recent operational highlights.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET
8/5/2021
Capricor Therapeutics will release its financial results for the second quarter ended June 30, 2021, after the market close on Thursday August 12, 2021.
-
Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
8/4/2021
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), announced today the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery.
-
Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
7/27/2021
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, today announced the appointment of Karimah Es Sabar to its Board of Directors, effective immediately.
-
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
6/17/2021
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), announced today that Capricor CEO, Linda Marbán, Ph.D., will provide an update on recent findings after a preliminary review of the Company’s ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002, at the Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference.
-
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
6/10/2021
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will participate in 1x1 meetings with investors and potential partners at BIO Digital 2021 being held June 10-11 and June 14-18, 2021.
-
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
4/29/2021
Capricor Therapeutics, a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced that it has signed an exclusive, worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics as part of the Company’s exosome technology portfolio.
-
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
1/19/2021
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricor’s Exosome Platform Advancement-
-
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
1/12/2021
—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims to expand Capricor’s manufacturing capacity for potential late-stage clinical trials and commercialization— —Process development to take place in Lonza’s Houston (TX) center of excellence—
-
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial
12/29/2020
Capricor Therape u tics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today that the independent Data and Safety Monitoring Board (DSMB) has completed its safety review for Capricor’s Phase II IN S PIR E study. The DSMB recommend
-
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
11/24/2020
Capricor Therapeutics, Inc. announced today that the first two patients have been dosed in its Phase 2 study evaluating intravenous infusion of CAP-1002
-
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
11/9/2020
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Scheduling Pre-IND Meeting with FDA to Discuss Clinical Strategy
-
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET
11/5/2020
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today, that it will release its financial results for the third quarter ended September 30, 2020, after the market close on Thursday, November 12, 2020. Company management will host a conference call and webcast to discuss its financial
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.